HeartSciences is a medical technology company dedicated to transforming the early detection of heart disease through Artificial Intelligence-Enhanced Electrocardiography (AI-ECG) solutions. By integrating advanced AI algorithms with traditional ECG technology, HeartSciences aims to identify previously undetectable cardiovascular conditions, thereby expanding the clinical utility of ECGs and facilitating earlier diagnosis and treatment. Key Features and Functionality: - MyoVista® wavECG™ Device: A high-performance 12-lead resting ECG device that incorporates proprietary AI-ECG algorithms. It provides both conventional ECG data and advanced diagnostic information related to cardiac dysfunction in a single test. - MyoVista Insights™ AI-ECG Cloud Platform: A cloud-based platform designed to deliver AI-ECG algorithms using existing ECG devices. It covers a range of important cardiovascular conditions and integrates seamlessly with existing clinical pathways. - Extensive AI-ECG Algorithm Portfolio: HeartSciences has developed one of the world's largest commercial portfolios of AI-ECG algorithms, covering a wide range of cardiovascular conditions. Primary Value and User Benefits: HeartSciences' AI-ECG solutions address the critical challenge of early heart disease detection. Traditional ECGs often fail to detect many heart conditions, leading to delayed diagnoses and treatments. By enhancing ECGs with AI, HeartSciences enables healthcare providers to identify heart disease at earlier stages, even in asymptomatic patients. This early detection facilitates timely interventions, improves patient outcomes, and has the potential to reduce healthcare costs associated with advanced-stage treatments. Moreover, the integration of AI-ECG technology into existing clinical workflows ensures that these advanced diagnostic capabilities are accessible across various healthcare settings, from large hospital systems to mobile testing services.